Is eHealth, Inc. overvalued or undervalued?

As of 31 October 2025, the valuation grade for eHealth, Inc. has moved from attractive to very attractive, indicating a strong positive shift in its perceived value. The company appears to be undervalued, supported by key ratios such as a P/E ratio of 6, a Price to Book Value of 0.20, and an EV to EBITDA of 0.40. In comparison, its peer Abacus Life, Inc. has a significantly higher P/E ratio of 164.30, highlighting eHealth's relative undervaluation within the industry.
Despite recent stock performance showing a year-to-date decline of 44.79% compared to a 16.30% gain in the S&P 500, eHealth's long-term returns over three years of 93.66% versus 76.66% for the benchmark suggest potential for recovery and growth. This combination of low valuation ratios and favorable long-term performance reinforces the argument that eHealth, Inc. is currently undervalued.